Treatment should be discontinued immediately at the first appearance of skin rash or any other serious adverse reactions. COTRIMOXAZOLE (GLOBAXOL) should not be given during pregnancy and to premature and newborn infants.
Special care should be exercised in treating patients with severe hepatic parenchymal damage as changes may occur in the absorption and metabolism of trimethoprim and sulfamethoxazole.
COTRIMOXAZOLE (GLOBAXOL) should not be given to infants below 6 weeks of age because of the risk of Kernicterus from the sulfonamide content.
An adequate fluid intake should be maintain to reduce the risk of crystalluria, but alkalinisation of the urine, increases urinary excretion of the sulfamethoxazole component but decreases urinary excretion of trimethoprim.